New hope for kidney disease patients: finerenone trial aims to reduce protein leakage
NCT ID NCT07181135
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug finerenone can lower protein levels in the urine of people with chronic kidney disease who are not taking certain blood pressure medications. About 180 adults will receive either finerenone or a placebo for 6 months. The goal is to see if finerenone helps protect kidney function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clínica Universidad de Navarra
Madrid, Spain
-
Clínica Universidad de Navarra
Pamplona, Spain
-
Hospital Clinico Universitario de Valencia
Valencia, Spain
-
Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
-
Hospital Universitario Dr Peset
Valencia, Spain
-
Hospital Universitario Puerta de Hierro
Madrid, Spain
-
Hospital Universitario de La Princesa
Madrid, Spain
-
Vall d'Hebron University Hospital
Barcelona, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk